The government has moved to curb the sale of syrup‑based medicines by requiring a doctor’s prescription. This step follows a series of child deaths linked to contaminated cough syrups and aims to restore confidence in India’s pharmaceutical export reputation.
Key Developments
- Removal of the word Schedule K from the Drugs Rules 1945, meaning cough syrups can now be sold only with a prescription.
- The change was announced in a draft notification in December 2025 and took effect in 2026.
- Contamination involved ethylene glycol (EG) and diethylene glycol (DEG), leading to over 300 child deaths across several countries since 2022.
- The WHO issued warnings in 2022 and 2023, questioning India’s export quality controls.
Important Facts
Most over‑the‑counter cough syrups in India are mixtures of bronchodilators, antihistamines and decongestants. In infants, these can cause tremors, heart palpitations, severe sedation or paradoxical agitation. The American Academy of Pediatrics warns that cough suppressants are largely ineffective for children under six and may mask serious conditions such as pneumonia or asthma.
Beyond formulation issues, the root cause of the recent deaths is poor manufacturing quality control, inadequate testing of raw materials, and weak regulatory oversight. The Indian Pharmacopoeia and the Pharmacopoeia Internationalis have updated methods to detect EG/DEG, yet batch testing failures persist.
India has roughly three dozen State drug controllers, who are chronically understaffed. Without a significant boost in inspector numbers, the new prescription rule may have limited impact in rural and semi‑urban areas where pharmacists often act as primary care providers.
Exam Relevance
Understanding this issue helps aspirants link health governance with economic and security concerns. The pharmaceutical sector is a major export earner; lapses affect trade balances (GS3: Economy) and India’s claim of being the "world’s pharmacy" (GS1: International Relations). The episode also illustrates the challenges of balancing industry lobbying with public safety—a recurring theme in governance and ethics (GS4: Ethics).
Way Forward
- Strengthen the inspectorate by increasing the number and training of State drug controllers.
- Mandate routine batch testing using the updated methods from the Indian Pharmacopoeia and enforce penalties for non‑compliance.
- Promote public awareness about the risks of self‑medication, especially for children under six.
- Encourage research into safer, non‑sedative cough remedies and align domestic standards with WHO guidelines.
Only a combination of stricter regulation, robust enforcement, and informed consumer behaviour can prevent future tragedies and safeguard India’s pharmaceutical reputation.